• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23488 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Somatrogon (growth disturbance) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Somatostatin analogs with lutetium-177 in neuroendocrine tumors]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Somapacitan (growth hormone deficiency) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Somapacitan (growth hormone deficiency, adults) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Solriamfetol (obstructive sleep apnoea) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Solriamfetol (obstructive sleep apnoea) - Addendum to Commission A21-129]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Solriamfetol (narcolepsy) - Benefit assessment according to §35a Social Code Book V]
2023     Canary Health Service [Software to support decisions for the administration of medicines in neonatal and paediatric intensive care units]
2023     Canary Health Service [Software applications for prevention and intervention in people at risk of suicide: effectiveness, safety and cost-effectiveness]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Addendum to Commission A17-35]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir (chronic hepatitis C) - Addendum to Commission A16-48]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir (chronic hepatitis C in children and adolescents) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir (chronic hepatitis C in children 3 to < 6 years of age) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/ velpatasvir/ voxilaprevir (hepatitis C, 12 to adolescents)
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Sofosbuvir and simeprevir-based schemes for the management of hepatitis C]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sodium zirconium cyclosilicate (hyperkalaemia) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Social isolation in the elderly: what measures can prevent or counteract social isolation?]
2007     Basque Office for Health Technology Assessment (OSTEBA) [Social inequalities in perinatal health in the Basque Autonomous Community]
2009     Committee for New Health Technology Assessment (CNHTA) [SNCA Gene Mutation Anaysis]
2009     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Smoking cessation among patients in general practice - a health technology assessment]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Smoking bans in public places]
2009     Committee for New Health Technology Assessment (CNHTA) [SMN1/SMN2 gene [Gene dosage test]]
2009     Committee for New Health Technology Assessment (CNHTA) [SMN1 gene, mutation[sequencing]]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Small study effect and publication bias in systematic reviews with meta-analyses]
2009     Committee for New Health Technology Assessment (CNHTA) [Small bowel transplantation]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Sling suspension in male urinary incontinence]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sleep position therapy for obstructive sleep apnoea]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sleep position therapy for obstructive sleep apnoea - Addendum to commission E20-07]
2008     Committee for New Health Technology Assessment (CNHTA) [SLC25A13 gene, mutation[sequencing]]
2009     Committee for New Health Technology Assessment (CNHTA) [SLC12A3 gene, mutation [sequencing]]
2022     National Authority for Assessment and Accreditation in Healthcare (INEAS) [SKYRIZI® (Risankizumab) for the treatment of moderate to severe plaque psoriasis in adults : A rapid review]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Skin substitutes in burn care]
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Skin cancer prevention: Guideline recommendations for primary and secondary prevention]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sitagliptin/metformin - Benefit assessment according to §35a Social Code Book V]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sitagliptin/Metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to § 35a Social Code Book V (expiry of the decision)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sitagliptin - Benefit assessment according to §35a Social Code Book V]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sitagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sirolimus (Facial angiofibroma in tuberous sclerosis) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sipuleucel-T (Addendum to Commission A14-38)]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sipuleucel-T - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Siponimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Siponimod (multiple sclerosis) - Addendum to Commission A20-10]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Single-use negative pressure wound therapy for acute and chronic wounds]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Single-donor platelet concentrate in patients with thrombocytopenia]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Simoctocog alfa - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     Andalusian Health Technology Assessment Area (AETSA) [Simeprevir in the treatment of chronic hepatitis C. Comparative efficacy and safety assessment]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Simeprevir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2010     The Swedish Council on Health Technology Assessment (SBU) [Silver-releasing dressings in treating chronic wounds]
2010     Committee for New Health Technology Assessment (CNHTA) [Silver in situ hybridization]
2010     Committee for New Health Technology Assessment (CNHTA) [Silver in situ hybridization test]
2010     The Swedish Council on Health Technology Assessment (SBU) [Silver dressings to treat chronic wounds]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Siltuximab - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2020     National Committee for Technology Incorporation (CONITEC) [Sibutramine for the treatment of obese patients]
2011     Committee for New Health Technology Assessment (CNHTA) [Sialendoscopy]
2014     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Sialendoscopy for the management of obstructive salivary gland disease]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Sialendoscopy for obstructive salivary gland disease]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Shoulder prosthesis in complex proximal humeral fractures]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Shoulder pain: appropriateness use of diagnostic imaging tests]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Shoulder arthroscopy: appropriate use]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Should one or two embryos be transferred in IVF]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Shear-wave elastography for liver fibrosis]
2010     Canary Health Service [Shared decision making in the choice of statins for patients with type two diabetes]
2009     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Shared care in catheterization of patients with long-term urinary catheter need]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [SGLT2 inhibitors in heart failure]
2009     Committee for New Health Technology Assessment (CNHTA) [SGCE gene, mutation[sequencing]]
2007     Basque Office for Health Technology Assessment (OSTEBA) [Sexually transmitted diseases. Situation in the Basque Autonomous Community. Effectiveness of preventive measures]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Setting research priorities, optimizing study design, and guiding the choice of relevant outcome measures in the evaluation of diagnostic (imaging) tests: an ancillary study of project numbers 1015 and 1139]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Setmelanotide (obesity and control of hunger in POMC, PCSK1 or LEPR deficiency obesity) - Assessment according to §35a (para. 1, sentence 11) Social Code Book VAuftraggeber: G-BA]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Setmelanotide (Bardet Biedl syndrome) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Serum procalcitonin levels as a diagnosis tool in acute bacterial respiratory tract infections]
2010     Andalusian Health Technology Assessment Area (AETSA) [Serum biomarkers panel for detecting early stage ovarian cancer]
2009     Committee for New Health Technology Assessment (CNHTA) [SERPINC1 exon deletion/duplication test [MLPA]]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Seroprevalence of Trypanosoma Cruzi infection in Latin American women of fertile age and during pregnancy in the Autonomous Community of the Basque Country]
1997     Finnish Office for Health Care Technology Assessment (Finohta) [Separate health care registers: a study of national and regional patient registers in Finland]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Seoul Cognitive Status Test]
2021     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Sentinel lymph node biopsy in oral cavity carcinoma: clinical effectiveness, safety, and cost-effectiveness]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Sentinel lymph node biopsy in breast cancer treatment: indications and contraindications]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Sentinel lymph node biopsy in breast cancer treatment: efficacy and safety]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Sentinel lymph node biopsy in breast cancer treatment: efficacy and safety]
2009     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Sentinel lymph node biopsy in breast cancer management: technical aspects]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Sensor-augmented insulin pump for diabetic patients]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Semaglutide (type 2 diabetes mellitus) - Addendum to Commission A20-93]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selumetinib (treatment of neurofibromas in neurofibromatosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selumetinib (neurofibromatosis) - Assessment according to §35a (para 1., sentence 11) Social Code Book V (expiry of the decision)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (thyroid cancer) - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (thyroid cancer) - Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (solid tumours) - Benefit assessment according to § 35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (RET mutant medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (RET fusion-positive thyroid cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (advanced NSCLC with RET fusion) - Benefit assessment according to § 35a SGB V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, second line) - Benefit assessment according to §35a Social Code Book V]